Title:Recent Advances in Pharmacological Interventions of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome
Volume: 27
Issue: 25
Author(s): Nasrin Aktar, Ahmed Moudud, Tingting Chen, Xiaoqing Gao, Hanhui Min, Meng Tang and Xiaohui Zhou*
Affiliation:
- Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198,China
Keywords:
Chronic prostatitis, chronic pelvic pain syndrome, irritative voiding, sexual dysfunction, pelvic pain, pharmacological interventions.
Abstract: Chronic prostatitis/chronic pelvic pain syndrome type III is related to irritative voiding, sexual dysfunction,
and pelvic pain. Chronic prostatitis/chronic pelvic pain syndrome weakens the quality of life and poses
adverse psychological effects on the patients. A wide range of treatments, including botulinum neurotoxins,
anti-inflammatories, alpha-blockers, phytotherapy, 5α-reductase inhibitors, phosphodiesterase type 4 inhibitor,
phosphodiesterase type 5 inhibitor, monoclonal antibody, anticholinergics, gabapentin, pregabalin is used clinically.
These therapies emphasize easing the symptoms in specific areas without curing the fundamental cause
where the outcome of the treatment is not completely satisfactory. This review article explains the recent pharmacological
treatments of chronic prostatitis/chronic pelvic pain syndrome in detail and offers a future perspective
to treat this condition.
